Avalglucosidase Alfa shortage — DE supply status & alternatives

Avalglucosidase Alfa

ATC A16AB22

🇦🇺 AUST R 346495 · Sanofi-Aventis Australia Pty Ltd

In supply · Australia

Nexviadyme

In supply · 🇦🇺 Australia · short in🇨🇦 CA🇩🇪 DE🇧🇪 BE

In supply in Australia

Reading today’s signals…

✓ Can I substitute?

Per normal rules

Confirm with prescriber

⇄ Best alternative

None listed

refer to prescriber

◷ Expected back

No estimate

No estimate provided

Product attributes reference data we hold

Brand names	Nexviadyme

ATC level 5	A16AB22

ATC level 4	A16AB

Therapeutic category	Auto-created by Federal Agency for Medicines and Health Products — PharmaStatus scraper

Controlled substance	No

Marketing-authorisation holders	Sanofi-Aventis Australia Pty Ltd

Registrations on file	1

Patient information leaflet (PIL)	Not on file

Summary of product characteristics (SPC)	Not on file

Trade price 🇦🇺 Australia · awaiting price ingest

🇦🇺 AU

Ex-manufacturer

—

Dispensed (DPMQ)

—

Pack

—

Not yet captured for Australia

Official pricing isn’t on file for this market yet. PBS (Australia), NHS Drug Tariff (United Kingdom) and CMS NADAC (United States) feeds are prioritised; this panel populates automatically once the data lands.

Substitution pathways 🇦🇺 Australia · TGA

—

No substitution instrument in force

Dispense per normal rules, or refer to the prescriber. No active SSSI/S19A instrument detected for this medicine.

Verified timeline regulator events

🇩🇪 3 July 2026

high reported

🇧🇪 3 July 2026

medium reported

🇧🇪 1 July 2026

medium reported

🇨🇦 29 June 2026

high reported

🇧🇪 9 Apr 2025

medium reported

🇧🇪 24 Mar 2025

medium reported

Registration recordmarketing-authorisation holders

Registrations & marketing-authorisation holders1 registration · 1 MA holder

Product	Strength	Form	Market	MA holder	Status
NEXVIAZYME avalglucosidase alfa powder for injection100mg/	100mg	—	🇦🇺 AU	Sanofi-Aventis Australia Pty Ltd	Active

For health-professional reference only. Mederti aggregates shortage and substitution information from official regulatory sources. It is not clinical advice and data may be incomplete or delayed. Confirm any substitution or supply decision against the primary regulator source, the prescriber, and current clinical references (e.g. AMH) before acting. Terms.